Clinical Research
corporate_fare

Provention Bio Inc.

Address
100 Morris Street

Sponsor Overview

assignment
1
sponsored trial
science
1
molecule
location_city
16
research centres
public
5
countries
person_search
16
investigators

Specializations

Type 1 Diabetes Mellitus

Clinical activity is centered on Type 1 Diabetes Mellitus, with interest in disease-modifying treatment for individuals affected by autoimmune beta-cell destruction and ongoing endocrine dysfunction.

  • Autoimmune diabetes
  • Recent-onset Type 1 Diabetes
  • Glycemic disease progression

The trial portfolio reflects a focus on maintaining long-term safety in the setting of immunotherapy used for Type 1 Diabetes management.

Immune-mediated Endocrine Disease

Research interest extends to the immune mechanisms underlying pancreatic islet injury and the clinical management of autoimmune endocrinopathy.

  • Immune tolerance
  • Islet preservation
  • Beta-cell protection

These areas align with therapeutic development aimed at altering the course of immune-driven diabetes.

Teplizumab Safety and Follow-up

Clinical research includes extended observation of teplizumab, with attention to its long-term safety profile in participants previously enrolled in recent-onset diabetes research.

  • Extended follow-up
  • Safety surveillance
  • Immunotherapy monitoring

This area supports continued evaluation of treatment-related effects in a chronic autoimmune setting.

Clinical Operations in Multinational Diabetes Research

The sponsor’s research footprint includes collaborative work across multiple sites and countries, with activity organized through clinical sciences and operations for diabetes-focused development.

  • Multicenter collaboration
  • Recruiting clinical research
  • Cross-border study coordination

Operational emphasis is directed toward supporting access to autoimmune diabetes studies in international settings.

Sponsored Trials

Trial Name Country Status
Long-Term Safety Evaluation of Teplizumab in Pediatric and Adolescent Patients with Recent-Onset Type 1 Diabetes Mellitus: An Extension of Study PRV-031-001Belgium BelgiumCzechia CzechiaFrance FranceGermany GermanyPoland PolandNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 1 total (0% not shared with other sponsors)

This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 16 sites collaborated multiple times

This sponsor has worked with 16 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Nutritional and Metabolic Diseases1 trial
    211 other sponsors

Partnered Research Centres

16 centres
location_city
assignment966
Assistance Publique Hopitaux De Marseille
Address
264 Rue Saint Pierre, 13005 Marseille
Learn morearrow_forward
location_city
assignment94
Centre Hospitalier De Pau
Address
4 Boulevard Hauterive, Cs 17595, 64046 Pau
Learn morearrow_forward
location_city
assignment478
Centre Hospitalier Universitaire De Dijon
Address
14 Rue Paul Gaffarel, 21000 Dijon
Learn morearrow_forward
location_city
assignment227
Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur
Address
Place Louise Godin 15, 5000 Namur
Learn morearrow_forward
location_city
assignment147
Centre Hospitalier Universitaire d’Orléans
Address
14 Avenue De L Hopital, Cs 86709, 45067 Orléans
Learn morearrow_forward
location_city
assignment14
Evangelisches Klinikum Bethel gGmbH
Address
Schildescher Strasse 99, Schildesche, 33611 Bielefeld
Learn morearrow_forward
Page 1 of 3

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Provention Bio Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.